CEBERT PHARMACEUTICALS ACQUIRES WORLDWIDE MARKETING RIGHTS OF METHADONE HCl

Ridgefield, CT (October 10, 2001) -- Cebert Pharmaceuticals, Inc. and Roxane Laboratories, Inc. announced the signing of an exclusive agreement for Cebert to acquire the worldwide marketing rights to Roxane’s narcotic addiction treatment product,  Methadone HCl.

Under the terms of the agreement, Cebert will take over all customer relations, sales and marketing, including, inventory management, customer service, order tracking, and invoicing.  Roxane will continue to manufacture and distribute the product on a contract basis for Cebert.

            “We are delighted with our agreement with Roxane Labs; it is truly a ‘win-win’ opportunity for both companies, and for patients seeking treatment for addiction and their caregivers,” said Royce L. Watkins, President and CEO of Cebert.  “We believe a small company that specializes in psychopharmaceuticals is especially positioned to provide customer-oriented, focused management of this product.”  Cebert and Roxane will work together to insure a smooth transition and continued, reliable service to clinics and their patients. 

Cebert is a specialty pharmaceutical company with a focus in psychopharmaceuticals, located in Birmingham, Alabama.

Roxane Laboratories, Inc. is a subsidiary of Boehringer Ingelheim Corporation, based in Ridgefield, Connecticut and a member of the Boehringer Ingelheim group of companies. 

The Boehringer Ingelheim group of companies, with headquarters in Ingelheim (Germany) is one of the 20 leading pharmaceutical firms in the world and reported revenues of almost US $5.8 billion in 2000.

Boehringer Ingelheim, which has some 140 affiliated companies worldwide, focuses on human pharmaceuticals and animal health. The human pharmaceuticals business, which accounts for 95% of sales, is comprised of prescription medicines, consumer health care products and chemicals and biopharmaceuticals for industrial customers. Research and development, production, and distribution facilities are located around the globe. In 2000, Boehringer Ingelheim spent almost US $914 million on R&D, equivalent to 15.6% of net sales.

For more information on Boehringer Ingelheim, please see the international Internet website www.boehringer-ingelheim.com

CONTACT:

Pamela DeMala

Boehringer Ingelheim Pharmaceuticals, Inc.

900 Ridgebury Road

Ridgefield, CT  06877-0368

(203) 798-4700 / Fax (203) 791-6220

www.rdg.boehringer-ingelheim.com

or

Cebert Pharmaceuticals, Inc.

George F. Bohorfoush, CFO

1200 Corporate Drive

Birmingham, AL  35242

(205) 981-0201 / Fax (205) 981-0279

www.cebert.com